Viromed Medical AG, a German medical technology company specializing in cold plasma technology, has announced that it has received approval in Turkey for its medical device ViroCAP® med, which carries the MDR Class IIa certification. The approval, reported via NEWMEDIAWIRE, allows the product to be used for medical applications on the Turkish market, particularly for the treatment of open wounds and intraoperative use.
The timing of the approval is significant: Viromed had not expected it until February or March 2027. Uwe Perbandt, CEO of Viromed Medical AG, called the approval “a significant success for our international market development” and noted that it follows the summer registration of ViroCAP® derma with Turkey’s National Medical Device Tracking System (ÜTS). He described the milestone as important for the commercial launch of the ViroCAP® technology in a strategically important healthcare market.
Viromed already holds binding minimum orders for 7,000 ViroCAP® derma/med devices through the end of 2028 for the Turkish market, and deliveries will now be made based on the approval granted. In parallel, the process for reimbursement by Turkish health insurers is already running. This approval thus lays the groundwork for further development of the Turkish market and continues Viromed’s international expansion strategy.
ViroCAP® med is designed for professional use by qualified medical personnel and supports the treatment of open wounds as well as intraoperative use of cold atmospheric plasma. The application is contactless and mobile, with each application planned to last one to two minutes while skin temperature remains below 40 degrees Celsius.
Beyond Turkey, Viromed and its partner Umeco have initiated approval processes for ViroCAP® med in additional Asian countries. A prerequisite for these efforts was the product’s prior approval as an MDR Class IIa medical device in the EU; outside the EU, local approval in each target country is required and is being pursued with distribution partners.
Separately, Viromed has achieved its first reimbursement of ViroCAP® by a statutory health insurer. A selective contract was concluded with a health insurer in Lower Saxony for an indication in intensive care: the treatment of patients with a left ventricular assist device (LVAD), focusing on preventing infections at the driveline exit site. The company is also in advanced discussions for further selective contracts with health insurers in three additional German federal states.
Further clinical evidence is expected soon. In November, a successfully completed retrospective study on the prevention of postoperative wound infections will be published. Additionally, Viromed is starting a randomized study on the use of ViroCAP® in LVAD patients and a further study on the technology’s use in the field of heart valves.
For more details, see the full release.


